Eton Pharmaceuticals Reports Record Q3 2026 Results and Raises Full-Year Guidance
Eton Pharmaceuticals (ETON) delivered a robust third quarter in 2026, characterized by significant revenue growth and record profitability. Net revenue reached $57.9 million, representing a 158% year-over-year increase driven largely by the inclusion of HEMANGEOL and organic expansion across its core portfolio. The company achieved an adjusted EBITDA margin of 49%, despite incurring a $3 million licensing payment for ASN-001. Driven by sustained momentum, management raised its full-year 2026 revenue guidance to over $175 million (up from $145 million) and increased its adjusted EBITDA margin forecast to above 40%. Notably, the company reached an annualized revenue run rate of $200 million, hitting a key fiscal year 2027 goal five quarters ahead of schedule. While clinical data for ET-700 showed lower efficacy in copper uptake compared to current standards, management is pivoting toward faster-release formulations.
Tickers: $ETON
Topics: EBITDA Margin Guidance Revision Profitability Revenue Growth